Search results for "Verteporfin"
showing 2 items of 12 documents
Photodynamic Therapy in Subfoveal Choroidal Neovascularisation
2002
Summary The exudative form of age-related macular degeneration (AMD) is the leading cause of blindness among people over 50 years of age in the western world. In 2–10% of cases a subfoveal choroidal neovascularisation develops. Conventional laser treatment leads to an unspecific destruction of the CNV including adjacent retinal structures. In addition, significant and immediate vision loss occurs, particularly in cases with central, subfoveal localization of the CNV.Photodynamic therapy (PDT) employing photochemical activation of verteporfin as a photosensitizer induces selective occlusion of CNV with minimal damage to the neurosensory retina and does not impair visual acuity. It became ava…
Evolving European guidance on the medical management of neovascular age related macular degeneration
2006
BACKGROUND: Until recently, only two options were available for the treatment of choroidal neovascularisation (CNV) associated with age related macular degeneration (AMD)-thermal laser photocoagulation and photodynamic therapy with verteporfin (PDT-V). However, new treatments for CNV are in development, and data from phase III clinical trials of some of these pharmacological interventions are now available. In light of these new data, expert guidance is required to enable retina specialists with expertise in the management of AMD to select and use the most appropriate therapies for the treatment of neovascular AMD. METHODS: Consensus from a round table of European retina specialists was obt…